John Baker

CEO, IMU Bioscience

Dr. John Baker is Chief Executive Officer of IMU Biosciences, where he is leading the company’s mission to harness AI-driven immune profiling to unlock breakthroughs in precision medicine. Before joining IMU in 2024, John spent eight years at Abcam as part of the Executive Team, guiding the company through rapid global expansion and its $5.7B acquisition by Danaher. Trained as a veterinarian at Cambridge and holding a DPhil in Clinical Medicine from Oxford, he has published on innate immunity and brings deep scientific and leadership experience from roles at Bain & Company and as a Non-Executive Director in biotech.

Amir Hasan

Chief Operating Officer, Ultromics

Amir has had a number of roles at Philips Healthcare ranging from marketing, business development, R&D and product management over the past 20 years. In his last role before joining Ultromics he was a Business Unit General Manager, leading a 300 person global team in Cardiology Informatics. 
Ultromics is a disruptive startup that utilizes AI to diagnose heart disease from Echocardiographic scans of the heart. They recently partnered with both J&J Innovative Medicine and Pfizer to bring a new diagnostic to the market for the detection of Amyloidosis for which both companies have a therapeutic. His experience in both large and small companies gives him a unique perspective on how to collaborate to drive innovation. 

Trevor Howe

Janssen Fellow, Director and Head of Translational Genomics, Johnson & Johnson Innovation

Trevor is a Janssen Fellow and Head of Translational Genomics for Johnson & Johnson Innovation. He is responsible for identifying and validating drug targets or pathways from human genetic signatures though internal and external collaborations.
He joined Janssen in 2003 where he formed the Molecular Informatics group to focus on structural biology, biophysics & computational methods for ligand identification and optimisation in all phases of pre-clinical drug discovery process.

Prior to Trevor’s current Johnson & Johnson/Janssen career, he headed the worldwide Computational Chemistry Council for Novartis from 1997 – 2003. He also led several immunology projects which resulted in successful clinical candidates for the respiratory disease therapeutic area. From 1990 – 1997 Trevor worked for Lilly establishing their computational chemistry department in the UK, developing Bayesian analysis methods. He was simultaneously a visiting researcher at the University of Oxford with Prof Graham Richards.
Trevor’s first degree was in Chemistry at the University of Exeter which was followed by a PhD at the University of East Anglia on small molecule conformation. From 1988 – 1990 he was a postdoctoral researcher at SUNY, Buffalo, USA studying glucosidase inhibition for applications to HIV.

Trevor serves on several UK Research Council scientific advisory bodies particularly in the area of genomics. He has been a visiting Industrial Fellow at Bristol University was a co-founder of the Phenotypic Discovery Initiative (http://npsc.ac.uk/consortia) which he established with the Universities of Oxford, Edinburgh and Dundee. In 2019 he was the J&J scientific lead for a consortium which executed the world’s biggest whole genome sequencing project on the 500,000 samples in the UK BioBank. He is the scientific lead for J&J’s involvement in Our Future Health (OFH, https://ourfuturehealth.org.uk) and represents all industry members on the Scientific Advisory Board to OFH. He has led J&J partnerships in utilisation of genomic data particularly in the area of non-coding variants.

Michalis Papadakis

CEO and Co-founder, Brainomix

Dr Michalis Papadakis is the CEO and co-founder of Brainomix. He leads the management team, commercial strategy, fund raising, and corporate partnerships. He has grown the company from the ground up, building the company’s global presence and has raised more than £30 million of private investment and public funding. When he founded Brainomix he was the Scientific Director of the preclinical stroke lab at the University of Oxford. He has a BSc Honours in Biochemistry from Imperial College London and a PhD in neurosciences from UCL School of Pharmacy. He has been an invited speaker at international scientific and innovation conferences.

Brainomix specializes in the creation of AI-powered software for better treatment decisions in stroke and lung fibrosis. With origins as a spin-out from the University of Oxford, Brainomix is an expanding commercial-stage company that has innovated award-winning software solutions used in more than 30 countries worldwide. Its Brainomix 360 platform, provides clinicians with the most comprehensive stroke imaging solution, driving increased treatment rates, and improving outcomes for patients.

Ian Wood

Clinical Director, Optum UK

Dr Ian Wood is a Clinical Director at Optum UK.  He joined EMIS in 2017 delivering clinical insight into the ongoing design, delivery and safety of EMIS Web, the company’s flagship product used in the majority of General Practice in the NHS.   He also led the business clinically in designing population health systems supporting clinical care, analytics and research within the UK.

Ian is a practicing NHS GP in Buckinghamshire, having trained at the University of Bristol and subsequently worked through NHS settings in Oxford and the surrounding Thames Valley region.  He is the Medical Director for Big Health, a digital therapeutics company building evidence-based mental health treatments in use in the NHS and US.  He has also held national and regional roles for the Royal College of General Practitioners.